Drug Trial Radar · NCT05534984
Study of Tecovirimat for Human Mpox Virus
Last checked: Nov 19, 2026Latest source record: Jun 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
719
Actual
Start
Sep 8, 2022
Primary completion
Oct 23, 2024
Study completion Feb 22, 2025
Sponsor
- Sponsor type
- NIH
- Collaborators
- SIGA Technologies
- First posted
- Sep 10, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study was to see if tecovirimat is safe and successful at treating mpox. The main questions were whether tecovirimat reduced time to lesion resolution and pain compared to placebo (no treatment).
Conditions
- MPOX
Interventions
Tecovirimat Oral CapsuleDrug
* Participants weighing 25 kg to less than 40 kg - Tecovirimat 400 mg every 12 hours for 14 days * Participants weighing 40 kg to less than 120 kg - Tecovirimat 600 mg every 12 hours for 14 days * Participants weighing 120 kg and over - Tecovirimat 600 mg every 8 hours for 14 days
Placebo for TecovirimatDrug
* Participants weighing 25 kg to less than 40 kg - Placebo for Tecovirimat 400 mg every 12 hours for 14 days * Participants weighing 40 kg to less than 120 kg - Placebo for Tecovirimat 600 mg every 12 hours for 14 days * Participants weighing 120 kg and over - Placebo for Tecovirimat 600 mg every 8 hours for 14 days
Tecovirimat Oral Capsule (Open Label)Drug
* Participants weighing \<3 kg - Tecovirimat 33.3 mg every 12 hours for 14 days * Participants weighing 3 kg to less than 6 kg- Tecovirimat 50 mg every 12 hours for 14 days * Participants weighing 6 kg to less than 13 kg - Tecovirimat 100 mg every 12 hours for 14 days * Participants weighing 13 kg to less than 25 kg - Tecovirimat 200 mg every 12 hours for 14 days * Participants weighing 25 kg to less than 40 kg - Tecovirimat 400 mg every 12 hours for 14 days * Participants weighing 40 kg to less than 120 kg - Tecovirimat 600 mg every 12 hours for 14 days * Participants weighing 120 kg and over - Tecovirimat 600 mg every 8 hours for 14 days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Cumulative Proportion With Clinical Resolution by Day 29Time frame: From study entry through 28 days of follow-up (i.e., Day 29)
Locations
54 sites in 6 countries. Site status is shown where the registry gives one.
Alabama CRS
Birmingham, Alabama
Kaiser Permanente Los Angeles Medical Center
Los Angeles, California
Los Angeles LGBT Center CRS
Los Angeles, California
UCLA CARE Center CRS
Los Angeles, California
University of California, Davis CRS
Sacramento, California
UCSD Antiviral Research Center CRS
San Diego, California
University of California, San Francisco HIV/AIDS CRS
San Francisco, California
Harbor University of California Los Angeles Center
Torrance, California
University of Colorado Denver NICHD CRS
Aurora, Colorado
University of Colorado Hospital CRS
Aurora, Colorado
Denver Public Health CRS
Denver, Colorado
University of Florida
Gainesville, Florida
University of Florida Jacksonville NICHD CRS
Jacksonville, Florida
University of Miami / Jackson Memorial Hospital
Miami, Florida
Univ. of South Florida (USF) College of Medicine A
Tampa, Florida
The Ponce de Leon Center CRS
Atlanta, Georgia
Rush University Cook County Hospital Chicago NICHD CRS
Chicago, Illinois
Johns Hopkins University CRS
Baltimore, Maryland
Massachusetts General Hospital CRS (MGH CRS)
Boston, Massachusetts
Brigham and Women's Hospital Therapeutics
Boston, Massachusetts
Henry Ford Hospital CRS
Detroit, Michigan
Washington University Therapeutics (WT) CRS
St Louis, Missouri
New Jersey Medical School Clinical Research Center
Newark, New Jersey
Weill Cornell Chelsea CRS
New York, New York
Mount Sinai West Samuels CRS
New York, New York
Harlem Prevention Center
New York, New York
Columbia Physicians & Surgeons (P&S) CRS
New York, New York
Weill Cornell Uptown CRS
New York, New York
Bronx-Lebanon Hospital Center NICHD CRS
New York, New York
Infectious Disease Clinical and Translational Research
New York, New York
University of Rochester Adult HIV Therapeutic
Rochester, New York
SUNY Stony Brook NICHD CRS
Stony Brook, New York
Duke University Medical Center CRS
Durham, North Carolina
Wake Forest Baptist Medical Center CRS
Winston-Salem, North Carolina
Cincinnati CRS
Cincinnati, Ohio
Case Western Reserve University CTU
Cleveland, Ohio
Ohio State University CRS
Columbus, Ohio
Penn Therapeutics CRS
Philadelphia, Pennsylvania
University of Pittsburgh CRS
Pittsburgh, Pennsylvania
St. Jude Children's Research Hospital ATN CRS
Memphis, Tennessee
Showing 40 of 54 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.